PMID- 34326893
OWN - NLM
STAT- MEDLINE
DCOM- 20211124
LR  - 20211124
IS  - 1748-6718 (Electronic)
IS  - 1748-670X (Print)
IS  - 1748-670X (Linking)
VI  - 2021
DP  - 2021
TI  - A Comprehensive Evaluation of miR-144-3p Expression and Its Targets in Laryngeal 
      Squamous Cell Carcinoma.
PG  - 6684186
LID - 10.1155/2021/6684186 [doi]
LID - 6684186
AB  - Laryngeal squamous cell carcinoma (LSCC) is an aggressive type of head and neck 
      squamous cell carcinoma (HNSCC) with a relatively high rate of morbidity and 
      mortality. An altered miR-144-3p level in LSCC with a small number of patients 
      has been previously reported. However, the clinical implication of miR-144-3p and 
      its involved mechanism underlying this disease is not clearly elucidated. In this 
      work, we aimed to confirm the expression of miR-144-3p with larger samples and 
      also to identify target genes for the investigation of the underlying mechanism 
      of miR-144-3p in LSCC. The levels of miR-144-3p were downregulated in 155 samples 
      of LSCC tissues as compared to 26 non-LSCC samples (SMD: -0.78; 95% confidence 
      interval (CI): -1.23, -0.32). The AUC of 0.90 in the summarized ROC curve also 
      indicated a potential ability to differentiate LSCC from non-LSCC tissues, with a 
      sensitivity of 0.78 and a specificity of 0.88. With respect to the molecular 
      mechanism, we predicted the potential targets from online-based prediction, 
      peer-reviewed publications, and RNA-seq and microarray data. In particular, the 
      genes influenced by transfection with miR-144-3p in the LSCC FaDu cell line were 
      collected from the microarray GSE56243. Lastly, 12 novel targets for miR-144-3p 
      in LSCC were obtained by different algorithms. In conclusion, our study confirmed 
      the loss or downregulation of miR-144-3p in LSCC, which might contribute to the 
      LSCC tumorigenesis and progression via regulation of the 12 novel targets, such 
      as IL24, ITGA6, and CEP55. In the future, further investigations are required to 
      validate the present results.
CI  - Copyright (c) 2021 Bin-Yu Mo et al.
FAU - Mo, Bin-Yu
AU  - Mo BY
AUID- ORCID: 0000-0001-8969-6152
AD  - Department of Otolaryngology, Liuzhou People's Hospital of Guangxi, No. 8 
      Wenchang Rd., Liuzhou, Guangxi Zhuang Autonomous Region, 545006, China.
FAU - Pang, Jin-Shu
AU  - Pang JS
AUID- ORCID: 0000-0002-1919-4859
AD  - Department of Radiotherapy, Guangxi Medical University Cancer Hospital, No. 71 
      Hedi Rd., Nanning, Guangxi Zhuang Autonomous Region, 530021, China.
FAU - Dai, Wen-Bin
AU  - Dai WB
AUID- ORCID: 0000-0003-4190-6805
AD  - Department of Pathology, Liuzhou People's Hospital of Guangxi, No. 8 Wenchang 
      Rd., Liuzhou, Guangxi Zhuang Autonomous Region, 545006, China.
FAU - Su, Ya-Si
AU  - Su YS
AUID- ORCID: 0000-0003-4890-4116
AD  - Department of Pathology, Liuzhou People's Hospital of Guangxi, No. 8 Wenchang 
      Rd., Liuzhou, Guangxi Zhuang Autonomous Region, 545006, China.
FAU - Jiang, Wei
AU  - Jiang W
AUID- ORCID: 0000-0003-4564-8356
AD  - Department of Educational Administration, Guangxi Medical University Cancer 
      Hospital, No. 71 Hedi Rd., Nanning, Guangxi Zhuang Autonomous Region, 530021, 
      China.
FAU - Huang, Su-Ning
AU  - Huang SN
AUID- ORCID: 0000-0001-9911-9084
AD  - Department of Radiotherapy, Guangxi Medical University Cancer Hospital, No. 71 
      Hedi Rd., Nanning, Guangxi Zhuang Autonomous Region, 530021, China.
LA  - eng
PT  - Journal Article
DEP - 20210716
PL  - United States
TA  - Comput Math Methods Med
JT  - Computational and mathematical methods in medicine
JID - 101277751
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (Cep55 protein, human)
RN  - 0 (ITGA6 protein, human)
RN  - 0 (Integrin alpha6)
RN  - 0 (Interleukins)
RN  - 0 (MIRN144 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (TNC protein, human)
RN  - 0 (Tenascin)
RN  - 0 (interleukin-24)
SB  - IM
MH  - Cell Cycle Proteins/genetics/metabolism
MH  - Cell Line, Tumor
MH  - Computational Biology
MH  - Disease Progression
MH  - Down-Regulation
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Gene Ontology
MH  - Humans
MH  - Integrin alpha6/genetics/metabolism
MH  - Interleukins/genetics/metabolism
MH  - Laryngeal Neoplasms/*genetics/metabolism
MH  - Male
MH  - MicroRNAs/*genetics/metabolism
MH  - Middle Aged
MH  - Squamous Cell Carcinoma of Head and Neck/*genetics/metabolism
MH  - Tenascin/genetics/metabolism
PMC - PMC8302387
COIS- The authors declare that there are no conflicts of interest regarding the 
      publication of this article.
EDAT- 2021/07/31 06:00
MHDA- 2021/11/25 06:00
PMCR- 2021/07/16
CRDT- 2021/07/30 06:44
PHST- 2020/10/12 00:00 [received]
PHST- 2021/06/04 00:00 [accepted]
PHST- 2021/07/30 06:44 [entrez]
PHST- 2021/07/31 06:00 [pubmed]
PHST- 2021/11/25 06:00 [medline]
PHST- 2021/07/16 00:00 [pmc-release]
AID - 10.1155/2021/6684186 [doi]
PST - epublish
SO  - Comput Math Methods Med. 2021 Jul 16;2021:6684186. doi: 10.1155/2021/6684186. 
      eCollection 2021.